{"id":7715,"date":"2025-06-27T17:07:10","date_gmt":"2025-06-27T14:07:10","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7715"},"modified":"2025-06-27T17:07:10","modified_gmt":"2025-06-27T14:07:10","slug":"acc-endorses-early-use-of-anti-obesity-medications-new-guidance-supports-semaglutide-and-tirzepatide","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/acc-endorses-early-use-of-anti-obesity-medications-new-guidance-supports-semaglutide-and-tirzepatide\/","title":{"rendered":"ACC Endorses Early Use of Anti-Obesity Medications: New Guidance Supports Semaglutide and Tirzepatide"},"content":{"rendered":"<div>ACC Endorses Early Use of Anti-Obesity Medications: New Guidance Supports Semaglutide and Tirzepatide<\/div>\n<div><\/div>\n<div>Date Published: June 20, 2025<\/div>\n<div>JACC. Jun 20, 2025. Epublished DOI:<\/div>\n<div><\/div>\n<div>Key Scientific Highlights<\/div>\n<div><span> 1. New Guidance by the ACC:<\/span><\/div>\n<div>The American College of Cardiology now recommends considering pharmacotherapy as a first-line treatment for eligible patients with obesity, rather than waiting for lifestyle changes to \u201cfail.\u201d<\/div>\n<div><span> 2. Combination Approach:<\/span><\/div>\n<div>While medications may be initiated early, lifestyle interventions (diet, physical activity) must still be offered alongside drug therapy.<\/div>\n<div><span> 3. Medications in Focus:<\/span><\/div>\n<div><span> \u2022 Semaglutide (GLP-1 agonist; Wegovy, Ozempic \u2013 Novo Nordisk)<\/span><\/div>\n<div><span> \u2022 Tirzepatide (Dual GIP\/GLP-1 agonist; Zepbound, Mounjaro \u2013 Eli Lilly)<\/span><\/div>\n<div>Both have shown significant weight loss effects and cardiovascular risk reduction.<\/div>\n<div><span> 4. Clinical Benefits:<\/span><\/div>\n<div><span> \u2022 Semaglutide: Proven cardiovascular benefit in patients with and without diabetes.<\/span><\/div>\n<div><span> \u2022 Tirzepatide: Also improves outcomes in sleep apnea and HFpEF; may result in slightly greater weight loss than semaglutide in some trials.<\/span><\/div>\n<div><span> 5. Guidance Emphasis:<\/span><\/div>\n<div><span> \u2022 Choice between drugs depends more on insurance coverage and availability than clinical superiority.<\/span><\/div>\n<div><span> \u2022 Weight management should be addressed by multidisciplinary teams, not individual cardiologists.<\/span><\/div>\n<div><span> 6. Expert Opinion:<\/span><\/div>\n<div>\u201cPatients should not be required to \u2018try and fail\u2019 lifestyle changes prior to initiating pharmacotherapy,\u201d<\/div>\n<div>\u2013 Dr. Olivia Gilbert, Chair of the ACC Guidance<\/div>\n<div><span> 7. Clinical Considerations:<\/span><\/div>\n<div><span> \u2022 The burden of obesity on cardiovascular disease (CVD) justifies active involvement from cardiologists.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2025.05.024\">https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2025.05.024<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ACC Endorses Early Use of Anti-Obesity Medications: New Guidance Supports Semaglutide and Tirzepatide Date Published: June 20, 2025 JACC. Jun 20, 2025. Epublished DOI: Key Scientific Highlights 1. New Guidance by the ACC: The American College of Cardiology now recommends considering pharmacotherapy as a first-line treatment for eligible patients with obesity, rather than waiting for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7715","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7715"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7715\/revisions"}],"predecessor-version":[{"id":7719,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7715\/revisions\/7719"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}